FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220740037> ?p ?o ?g. }

• W4220740037 endingPage "470" @default.
• W4220740037 startingPage "460" @default.
• W4220740037 abstract "Oncolytic adenoviruses (OAd) represent an attractive treatment option for cancer. Clinical efficacy of commonly utilized human adenovirus type 5 (Ad5)-based oncolytic viruses is limited by variable expression levels of the coxsackie- and adenovirus receptor (CAR) in tumor cells and high prevalence of neutralizing antibodies against human Ad5. However, previous studies have highlighted alternative human Ad types as promising candidates for oncolytic therapy. In this study, we generated novel OAds based on Ad1, -2, -5, and -6 derived from species C Ads. These OAds contain a 24-bp deletion in the early gene E1A for tumor selective replication and express the RNAi inhibitor P19. We examined these OAds for in vitro anticancer activity on various cancer cell lines derived from lung, colon, gynecologic, bone, and pancreatic carcinoma. In most surveyed cell lines, OAds based on Ad1, -2, and -6 demonstrated higher cell lysis capability compared with Ad5, suggesting enhanced oncolytic potential. Moreover, enhanced oncolytic activity was associated with P19 expression in a cell type-dependent manner. We further explored a A549 tumor xenograft mouse model to compare the novel OAds directly with Ad5 and H101, an oncolytic adenovirus used in clinical trials. These P19-containing OAds based on Ad1, -2, and -6 showed significantly decelerated tumor progression compared with H101, indicating better antitumor potency in vivo. Our studies provide a novel path for OAd development based on alternative Ad types with improved effectiveness by RNA interference suppression." @default.
• W4220740037 created "2022-04-03" @default.
• W4220740037 creator A5000963442 @default.
• W4220740037 creator A5021970972 @default.
• W4220740037 creator A5029285661 @default.
• W4220740037 creator A5033744844 @default.
• W4220740037 creator A5035282947 @default.
• W4220740037 creator A5042322752 @default.
• W4220740037 creator A5064561845 @default.
• W4220740037 creator A5075774381 @default.
• W4220740037 creator A5078154783 @default.
• W4220740037 date "2022-03-01" @default.
• W4220740037 modified "2023-09-27" @default.
• W4220740037 title "Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>" @default.
• W4220740037 cites W1241012260 @default.
• W4220740037 cites W1544229812 @default.
• W4220740037 cites W1965606294 @default.
• W4220740037 cites W1976892064 @default.
• W4220740037 cites W1992351692 @default.
• W4220740037 cites W1998150511 @default.
• W4220740037 cites W2007270424 @default.
• W4220740037 cites W2011683790 @default.
• W4220740037 cites W2014197652 @default.
• W4220740037 cites W2046035469 @default.
• W4220740037 cites W2048858285 @default.
• W4220740037 cites W2060570235 @default.
• W4220740037 cites W2080543048 @default.
• W4220740037 cites W2084244053 @default.
• W4220740037 cites W2128356141 @default.
• W4220740037 cites W2146376756 @default.
• W4220740037 cites W2152424167 @default.
• W4220740037 cites W2159143830 @default.
• W4220740037 cites W2169962588 @default.
• W4220740037 cites W2409321676 @default.
• W4220740037 cites W2520557605 @default.
• W4220740037 cites W2620042836 @default.
• W4220740037 cites W2741524965 @default.
• W4220740037 cites W2980179481 @default.
• W4220740037 cites W3032184746 @default.
• W4220740037 doi "https://doi.org/10.1158/1535-7163.mct-21-0240" @default.
• W4220740037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35027480" @default.
• W4220740037 hasPublicationYear "2022" @default.
• W4220740037 type Work @default.
• W4220740037 citedByCount "5" @default.
• W4220740037 countsByYear W42207400372022 @default.
• W4220740037 countsByYear W42207400372023 @default.
• W4220740037 crossrefType "journal-article" @default.
• W4220740037 hasAuthorship W4220740037A5000963442 @default.
• W4220740037 hasAuthorship W4220740037A5021970972 @default.
• W4220740037 hasAuthorship W4220740037A5029285661 @default.
• W4220740037 hasAuthorship W4220740037A5033744844 @default.
• W4220740037 hasAuthorship W4220740037A5035282947 @default.
• W4220740037 hasAuthorship W4220740037A5042322752 @default.
• W4220740037 hasAuthorship W4220740037A5064561845 @default.
• W4220740037 hasAuthorship W4220740037A5075774381 @default.
• W4220740037 hasAuthorship W4220740037A5078154783 @default.
• W4220740037 hasBestOaLocation W42207400371 @default.
• W4220740037 hasConcept C104317684 @default.
• W4220740037 hasConcept C121608353 @default.
• W4220740037 hasConcept C150903083 @default.
• W4220740037 hasConcept C159047783 @default.
• W4220740037 hasConcept C166703698 @default.
• W4220740037 hasConcept C202751555 @default.
• W4220740037 hasConcept C207001950 @default.
• W4220740037 hasConcept C2522874641 @default.
• W4220740037 hasConcept C2777283488 @default.
• W4220740037 hasConcept C49744831 @default.
• W4220740037 hasConcept C502942594 @default.
• W4220740037 hasConcept C54355233 @default.
• W4220740037 hasConcept C55493867 @default.
• W4220740037 hasConcept C67705224 @default.
• W4220740037 hasConcept C81885089 @default.
• W4220740037 hasConcept C82210918 @default.
• W4220740037 hasConcept C86803240 @default.
• W4220740037 hasConceptScore W4220740037C104317684 @default.
• W4220740037 hasConceptScore W4220740037C121608353 @default.
• W4220740037 hasConceptScore W4220740037C150903083 @default.
• W4220740037 hasConceptScore W4220740037C159047783 @default.
• W4220740037 hasConceptScore W4220740037C166703698 @default.
• W4220740037 hasConceptScore W4220740037C202751555 @default.
• W4220740037 hasConceptScore W4220740037C207001950 @default.
• W4220740037 hasConceptScore W4220740037C2522874641 @default.
• W4220740037 hasConceptScore W4220740037C2777283488 @default.
• W4220740037 hasConceptScore W4220740037C49744831 @default.
• W4220740037 hasConceptScore W4220740037C502942594 @default.
• W4220740037 hasConceptScore W4220740037C54355233 @default.
• W4220740037 hasConceptScore W4220740037C55493867 @default.
• W4220740037 hasConceptScore W4220740037C67705224 @default.
• W4220740037 hasConceptScore W4220740037C81885089 @default.
• W4220740037 hasConceptScore W4220740037C82210918 @default.
• W4220740037 hasConceptScore W4220740037C86803240 @default.
• W4220740037 hasFunder F4320308022 @default.
• W4220740037 hasIssue "3" @default.
• W4220740037 hasLocation W42207400371 @default.
• W4220740037 hasLocation W42207400372 @default.
• W4220740037 hasLocation W42207400373 @default.
• W4220740037 hasOpenAccess W4220740037 @default.
• W4220740037 hasPrimaryLocation W42207400371 @default.

• next